SPL receives positive FDA feedback on DEP SN38 for PROC
Released
Released
Announcement PDF
ASX Announcement
Starpharma receives positive feedback from
FDA on DEP® SN38 clinical pathway for
platinum-resistant ovarian cancer
•
Starpharma has met with the US FDA to discuss the clinical pathway options for DEP®
SN38 in Platinum-Resistant Ovarian Cancer (PROC), which the FDA recognises as a
patient group with significant unmet need.
•
During the meeting, the FDA provided positive feedback on Starpharma’s proposed
clinical development plan for DEP® SN38, confirming the applicability of the “505(b)(2)”
registration pathway and the potential for Fast Track designation and accelerated
approval.
•
The FDA’s feedback provides confidence for an Investigational New Drug (IND) application
for DEP® SN38, supporting our ultimate goal of licensing the product.
Melbourne, Australia; 19 December 2024: Starpharma (ASX: SPL, US OTC: SPHRY), an
innovative biotechnology company with two decades of experience in advancing dendrimer
technology from the lab to the patient, today announces a positive development regarding its
DEP® SN38 (DEP® irinotecan) program following a meeting with the US Food and Drug
Administration (FDA).
The purpose of the meeting was to confirm the regulatory approval pathways and seek regulatory
guidance on the design of a Phase 2/3 clinical program aimed at obtaining registration for DEP®
SN38 in patients with platinum-resistant ovarian cancer in the US.
Key Outcomes from the Meeting with the US FDA
The FDA agreed with Starpharma’s proposal that DEP® SN38 could be considered for FDA Fast
Track designation, acknowledging that platinum-resistant ovarian cancer is a serious condition
with significant unmet medical need.
The FDA also agreed that a “505(b)(2)” regulatory approval pathway is appropriate for DEP® SN38,
as the product delivers the active moiety of the FDA-approved drug, irinotecan (Camptosar®). The
505(b)(2) pathway allows Starpharma to utilise existing FDA findings of safety and efficacy for an
already approved drug, potentially streamlining the approval process by removing the need for
some additional studies.
The FDA indicated that DEP® SN38 may qualify for accelerated approval based on an interim
analysis of early surrogate endpoints from the proposed Phase 2/3 clinical trial program. Final
outcomes will depend on the results of these studies and the overall data package; however, this
accelerated approval could provide early access to DEP® SN38 for patients with platinumresistant ovarian cancer.
The proposed clinical program for achieving both accelerated and full approval of DEP® SN38
involves comparing the safety and efficacy of DEP® SN38—whether alone or in combination with
other anticancer agents—against single-agent chemotherapies, such as paclitaxel, topotecan
and pegylated liposomal doxorubicin, either as monotherapy or in combination with other agents.
During the meeting, the FDA offered valuable guidance on the study design, particularly in defining
the target patient population, study endpoints, and biostatistical aspects. The agency
emphasised the importance of ensuring that DEP® SN38 is applicable to a broad range of patients
with platinum-resistant ovarian cancer.
Overall, the feedback and collaborative discussions with the FDA reflect a positive and
constructive interaction for Starpharma, clarifying the pathways for clinical development and
regulatory approval of DEP® SN38. The FDA’s feedback provides confidence for an Investigational
New Drug (IND) application for DEP® SN38, which could be advanced by a commercial partner.
Starpharma was supported in the meeting by a team of external clinical, regulatory and
biostatistics advisers. Robert L. Coleman, MD FACOG FACS, one of the world’s leading
gynaecologic oncologists and experts in the treatment of, and development of new agents for,
ovarian cancer, advised Starpharma on its DEP® SN38 development program and attended the
FDA meeting as a representative of Starpharma. Dr Coleman provided real-world expertise on the
clinical management of ovarian cancer and the design of registrational clinical trials for this
indication.
Following the meeting with the FDA, Dr Coleman commented:
“Starpharma’s meeting with the FDA provided clear guidance on the most efficient path forward
for the development and eventual registration of DEP® SN38 as a promising new treatment for
patients with platinum-resistant ovarian cancer. This disease represents a significant unmet
medical need, and the FDA demonstrated a clear, positive intention to work constructively with
the company on the DEP® SN38 program, with the goal of bringing a much-needed new therapy to
patients with platinum-resistant ovarian cancer as rapidly as possible.”
Cheryl Maley, Starpharma’s Chief Executive Officer, commented:
“While we focus on maximising the value of our DEP® clinical assets, it is important to ensure we
have the best asset package for a potential partner. We have worked hard to create a highly
attractive opportunity for prospective partners.
“This feedback from the US FDA marks an important milestone, supporting the IND submission,
which a partner can advance through further development, registration, and commercialisation.
We are encouraged by the FDA’s guidance, which validates our approach and allows us to
proceed confidently with the proposed clinical pathways for DEP® SN38.”
DEP® SN38 | Starpharma’s Priority DEP® Candidate for Out-Licensing
DEP® SN38 is Starpharma’s priority clinical-stage DEP® asset for licensing. It is a novel dendrimerdrug conjugate of the topoisomerase I (TOP1) inhibitor, SN38, which is the active metabolite of
irinotecan (Camptosar®). DEP® SN38 has demonstrated highly encouraging anticancer results in
a Phase 1/2 study in patients with a range of advanced cancers, including colorectal and platinumresistant ovarian cancer (PROC). These results were presented at the American Society of
Oncology (ASCO) 2024 Annual Meeting in June 2024. Following a strategic review of the program,
Starpharma has prioritised PROC as a key indication, given its significant unmet patient need,
commercial opportunities, and regulatory considerations.
2
Platinum-Resistant Ovarian Cancer | A Patient Group with Significant Unmet Need
In 2022, there were an estimated 325,000 new cases of ovarian cancer worldwide, and 207,000
deaths1. Platinum-resistant and platinum-refractory ovarian cancer are the largest unmet needs
within the ovarian cancer indication. Nearly all patients who have recurrent ovarian cancer
become resistant to platinum-based therapies, which are the mainstay of initial cancer treatment.
Effective treatment options for patients who are platinum-resistant/refractory are limited, and the
prognosis is poor.
About Starpharma
Starpharma ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing
dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve
improved health outcomes and quality of life through the application of our unique dendrimer technology.
Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure,
high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.
Starpharma’s portfolio of dendrimer-based products includes three clinical-stage DEP® (dendrimer enhanced product) assets,
preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.
For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn.
WE Communications
Hannah Howlett
+61 450 648 064
WE-AUStarPharma@weworldwide.com
Starpharma Holdings Limited
Cheryl Maley, Chief Executive Officer
Justin Cahill, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067
Disclosure
This ASX Announcement was
authorised for release by the Chair,
Mr Rob Thomas.
Forward-Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking
terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”,
“potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied
discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance
or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s
and other authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be
approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding
the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional
analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain
patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and
additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from
those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and
does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or
developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not
necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or
reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise,
representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.
1
https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf
3
Share your feedback
Discover